November 16, 2015 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Ocata Therapeutics Inc (NASDAQ:OCAT), was announced concerning whether the takeover of Ocata Therapeutics Inc by Astellas Pharma Inc is unfair to NASDAQ:OCAT stockholders.

The investigation by a law firm concerns whether certain officers and directors of Ocata Therapeutics Inc breached their fiduciary duties owed to NASDAQ:OCAT investors in connection with the proposed acquisition.

On November 9, 2015, Astellas Pharma Inc. and Ocata Therapeutics Inc (NASDAQ:OCAT) announced that they have entered into an agreement. Under the agreement, Astellas Pharma Inc will acquire Ocata Therapeutics Inc (NASDAQ:OCAT) through Laurel Acquisition Inc., a wholly-owned subsidiary of Astellas US Holding, Inc. . Pursuant to the agreement, Laurel Acquisition Inc will commence a tender offer for all outstanding shares of common stock of Ocata Therapeutics Inc (NASDAQ:OCAT), for a price of US$8.50 per share in cash.

However, the investigation concerns whether the offer is unfair to NASDAQ:OCAT stockholders. More specifically, the investigation concerns whether the Ocata Therapeutics Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.